Efficacy of Intrathecal Morphine for Postoperative Analgesia with or without Suprainguinal Fascia Iliaca Block After Total Hip Arthroplasty: A Double-Blind Randomized Clinical Trial

Centre hospitalier universitaire de Liege0 sites114 target enrollmentFebruary 23, 2024

Overview

No summary available.

Registry

who.int

Start Date

February 23, 2024

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Adult man/women over 18 and less 85 years old, American Society of Anesthesiologists (ASA) Physical Status 1 or 2 or 3, Able to speak, read and understand French, Admitted for scheduled elective total hip replacement surgery with spinal anesthesia

•Pregnant women (or woman of childbearing potential who are breastfeeding or not taking an effective contraception, defined as methods that can achieve a failure rate of less than 1% per year when used consistently and correctly, cfr. CTFG Guidelines Recommendations related to contraception and pregnancy testing in clinical trials”), Any patients where intrathecal morphine low dose (100 mcg) is contraindicated, Patients over 85 years old, Acute respiratory failure, Patients with acute abdominal syndrome, spasm of the sphincter of Oddi, bile duct contraction, pyloric spasm, intracranial hypertension, convulsive states, coma., Patients with alcohol intoxication, barbiturate intoxication or acute porphyria., Patients with peripheral neuropathy or other severe neurological pathology, Patients unable to give consent, Patients with chronic pain syndromes or chronic opioid addiction (more than 20 mg per day of equivalents oral morphine), Chronic renal failure (glomerular filtration rate \< 45 mL/min/1\.73 m2\), Severe liver failure, Recent (\<12 months) thrombo\-embolic events, Suspected or confirmed allergy to local anesthetics or morphine, Allergy or hypersensitivity to the active ingredient or to any of the excipients of MORPHINE HCl STEROP, MINI\-PLASCO NaCl BBRAUN 0,9% or Naropin 0\.75%